DOCSLIB.ORG

Implication of Monoclonal Antibody for Covid-19

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Implication of Monoclonal Antibody for Covid-19 Journal of Institute of Science and Technology, 25(2), 133-139 (2020) ISSN: 2469-9062 (print), 2467-9240 (e) © IOST, Tribhuvan University Doi: https://doi.org/10.3126/jist.v25i2.33750 Review Article IMPLICATION OF MONOCLONAL ANTIBODY FOR COVID-19 TREATMENT Reshma Tuladhar* Central Department of Microbiology, Tribhuvan University, Kathmandu, Nepal *Corresponding author: [email protected] (Received: September 10, 2020; Revised: November 25, 2020; Accepted: November 30, 2020) ABSTRACT Coronavirus induced disease-19 (COVID-19) pandemic affecting entire world has continued to pose threat despite nearly a year of its onset. With more than 50 vaccine candidates targeting COVID-19 on trials and 15 at the final stage of testing, wide availability to the general public is still a long way to go. Thus alternative therapeutics is in the progress to minimize the effect of COVID-19. This systematic review evaluated the articles related to immunotherapy for COVID- 19. PubMed database was used to search for keywords; COVID-19, immunotherapy, and monoclonal antibody for relevant publications of the year 2020. The review was performed based on PRISMA protocol and the final 20 articles were included in the final review. These studies demonstrated that Tocilizumab, the monoclonal antibody that blocks IL- 6 receptors has improved outcome in COVID-19 infected patients. Keywords: Immunotherapy, Monoclonal antibody, PRISMA, SARS-CoV-2, Tocilizumab. immune response against SARS-CoV-2 infection INTRODUCTION contributing to the severity of the disease (Li et al., 2020). The pandemic of Corona Virus Induced Disease-2019 Containment of COVID-19 has also been challenged by (COVID-19) outbreak caused by Severe Acute an ambiguous pathogenesis mechanism. This has lead to Respiratory Syndrome Corona virus 2 (SARS-CoV-2) has an uncertainty in the therapeutics specifically targeting claimed over 1.7 million lives with more than 76 million SARS-CoV-2. The recently introduced vaccines approved infected globally (WHO, 2020). This highly contagious after the third phase of trial are yet to be assessed. disease spread by the respiratory droplets of infected Immunotherapy has been an efficient option considering person and has expanded across the world due to high its successful use against the closely related viruses transmission rate. Compared to the closely related beta SARS-CoV and MERS-CoV. Thus the purpose of this coronaviruses, the Middle East Respiratory Syndrome article is to review the use of monoclonal antibody, as an Coronavirus (MERS-CoV) and Severe Acute Respiratory immunotherapeutic against novel corona virus SARS- Syndrome Coronavirus (SARS-CoV), transmission rate in CoV-2 to ameliorate the condition of patient. SARS-CoV-2 is relatively high with large fraction contributed by asymptomatic carriers (Al-Tawfiq & METHODS Gautret, 2019; Wilder-Smith et al., 2005). The disease Search strategy induced by SARS-CoV-2 range from asymptomatic, noted without any signs and symptoms to symptomatic mild A systematic literature review was performed to phase involving upper airway and/or severe lethal state summarize information on monoclonal antibody infiltrating the lungs with progression to acute respiratory therapeutics for COVID-19 following the Preferred distress syndrome (ARDS) (Asadi et al., 2020; Shi et al., Reporting Items for Systematic Reviews and Meta- 2020). Analysis (PRISMA) guidelines. The main cause of death in COVID-19 infected patient is A literature search was conducted using PubMed database ARDS, which is associated with uncontrolled for keywords such as, COVID-19, immunotherapy, inflammatory response resulting from the release of pro- monoclonal antibody, and related words. The search inflammatory cytokines and chemokines- the cytokine included published articles for the year 2020. Title and storm (Li et al., 2020). Patients with COVID-19 have abstracts were reviewed to detect the related articles. increased plasma concentration of inflammatory Articles that have mentioned about immunotherapy for cytokines, such as Interleukins (IL), and over expression COVID-19 were selected. The articles with only abstract of tumor necrosis factor α (TNF α), granulocyte were excluded. Similarly articles that did not mention macrophagy-colony stimulating factors (GM-CSF), about the immunotherapeutic for the treatment of monocyte chemoattractant protein1, macrophage infection due to SARS-CoV-2 but only SARS, MERS, inflammatory protein 1 alpha, and interferon-γ-inducible other viruses and ailments were excluded. The full texts of protein 10 (Rothan et al., 2020). Cytokine release the relevant articles were read to decide on whether they syndrome has been suggested to hinder the adaptive could be included. Implication of monoclonal antibody for COVID-19 treatment Data extraction and presentation articles and experiment protocols were not considered so 37 such articles were excluded in the initial search. Then Data from the articles were extracted after reading the from the remaining 127 articles, 59 were excluded after articles which were presented in the tables as summary. full text screen since full text could not be retrieved for This review addressed six domains: drug name, target site, some while others were not related to monoclonal route of administration, outcome of treatment, authors, antibody therapeutics. Finally 48 articles without data on and article type. SARS-CoV-2, but rather MERS, SARS, cancer and RESULTS arthritis were excluded. A total of 20 articles were included in the final review (Fig. 1). A total of 164 non-duplicate potentially eligible articles were retrieved from the database search. The review Fig. 1. The article search flow chart From the extracted data, humanized monoclonal antibody 2020). Recovery in the patient with marked decreased C- used for SARS-CoV-2 incorporated were Tocilizumab, reactive protein (CRP) level in blood and improvement in Sarilumab, Itolizumab, Siltuximab, Infliximab and inflammatory markers with reduced fever were the Lenzilumab. The monoclonal antibodies that target commonly observed features in the patient treated with interleukin-6 receptor included in Table 1 are Tocilizumab these interleukin-6 receptor blockers. The recovery time and Sarilumab. They are administered intravenously, however varied with the authors. The improvement period although some have been introduced subcutaneously into ranged from 5 days to two weeks as mentioned in most of the patient (Hassoun et al., 2020; Montesarchio et al., the literature. Substantial research articles available on 134 R. Tuladhar Tocilizumab treatment demonstrated faster recovery compared to Sarilumab. Table 1. Overview of interleukin 6 receptor target monoclonal antibody for COVID-19 treatment Target Route of Drug name site administration Outcome of treatment Author Article type CRP decreased significantly, IL6 elevated at beginning then decreased afterwards Luo et al. (2020) Research CRP decreased within 2-6 Di Giambenedetto et days. IL6 was not detected al. (2020) Research Improvement in inflammatory markers within 7 days, improvement in clinical Hassoun et al. Subcutaneous syndrome (2020) Research CRP decreased Tocilizumab significantly, fever normal Intravenous after 1 day Xu et al. (2020) Research CRP decreased, fever reduced, peripheral Intravenous lymphocyte increased Zhao (2020) Research Interleukin CRP decreased, fever 6 receptor reduced, radiological Intravenous improvement Alattar et al. (2020) Temp returned to normal quickly after treatment, 20 out of 21 patients discharged after 2 weeks, no adverse effect, Fu et al. (2020) Commentary 89.7 % patients improved Gremese et al. Intravenous in 19 days, (2020) Research CRP level decreased, mostly below upper normal Montesarchio Subcutaneous range within 5 days et al. (2020) Report Sarilumab CRP normalized in 6 days compared to 12 days in Della-Torre et al. Intravenous control group (2020) Report Caballero Bermejo Partial improvement et al. (2020) Trial The anti-CD6 monoclonal antibody, Itolizumab, improvement in cytokine level in serum with decreased decreased the level of IL-6 in the serum within 48 hours IL6 and IL8 when Infliximab, the TNF alpha target was of intravenous administration (Table 2). Similarly, administered intravenous. Lenzilumab, the granulocyte- Siltuximab, which directly binds Interleukin-6 delayed monocyte colony stimulating factor (GM-CSF) target, did normalization of IL-6 compared to Tocilizumab when not improve the symptoms within 24 hours of intravenous administered subcutaneous. Reduction of CRP in 76 % administration (Melody et al., 2020) but improvement in patient with 33 % clinical improvement was reported in a CRP and inflammatory cytokines was reported in other research (Table 2). Similarly, a case study reported an study (Temesgen et al., 2020). 135 Implication of monoclonal antibody for COVID-19 treatment Table 2. Overview of monoclonal antibody with different target site for COVID-19 treatment Route of Article Drug name Target site administration Outcome of treatment Author type Anticipated in treating cytokine Loganathan et al. Intravenous storm, anti-inflammatory (2020) Trial Circulating IL6 decreased within CD6 Itolizumab Intravenous 48 hrs. Diaz et al. (2020) Research receptor Intravenous Serum IL6 decreased after 48 hrs Atal et al. (2020) Research IL6 decreased after 1 dose in 48 Saavedra et al. Intravenous hours (2020) Research Delayed normalization of IL6 Palanques Pastor Subcutaneous compared to Tocilizumab et al. Report Siltuximab Interleukin-6
Load more

Recommended publications
  • Presentation
    Strategies to support the COVID-19 response in LMICs A virtual seminar series Therapeutics Landscape for COVID-19 Natasha Mubeen Chida, MD MSPH Associate Program Director, Infectious Disease Fellowship Program Assistant Professor, Division of Infectious Diseases Johns Hopkins University School of Medicine Objectives • Review biological plausibility of Remdesivir for SARS-CoV-2 treatment • Review clinical data on Remdesivir • Review biological plausibility of Hydroxychloroquine for SARS-CoV-2 treatment • Review clinical data on Hydroxychloroquine • Discuss cytokine release syndrome in COVID-19 • Discuss use of anti IL-6 blockade for management of CRS • State ongoing clinical trials for Remdesivir, hydroxychloroquine, IL-6 blockade Sample of COVID-19 Therapeutic Landscape Antivirals Immune Modulators Other Baloxavir Anakinra ACEI/ARB Chloroquine/Hydroxychloroquine Convalescent Plasma Ascorbic Acid DAS-181 Corticosteroids Azithromycin Favipiravir IVIG Epoprostenol Interferon Lenzilumab Indomethacin Lopinavir/Ritonavir Ruxolitinib Ivermectin Neuraminidase inhibitors Sarilumab Niclosamide Remdesivir Sirolimus Nitazoxanide Ribavarin Tocilizumab Statins Umifenovir Acalabrutinib SARS-CoV-2 Liu C, et al. ACS Cent Sci. doi: 10.1021/acscentsci.0c00272 (2020). Jiang S, Hillyer C, Du L. Trends Immunol doi: 10.1016/j.it.2020.03.007 (2020). “Antivirals” Remdesivir • 2013 Ebola outbreak • CDC/USAMRIDD/Gilead Sciences identified nucleoside lead à prodrug, RDV • Metabolized to active form, adenosine nucleoside analog • Interferes with RNA polymerase • Evades
    [Show full text]
  • Biologic Armamentarium in Psoriasis
    Vol 9, Issue 1, 2016 ISSN - 0974-2441 Review Article BIOLOGIC ARMAMENTARIUM IN PSORIASIS GANESH PAI1*, NITHIN SASHIDHARAN2 1Medical Director, Derma-Care ‘The Trade Centre’, Mangalore - 575 003, Karnataka, India. 2Consultant Clinical Pharmacologist, Derma-Care ‘The Trade Centre’, Mangalore - 575 003, Karnataka, India. Email: [email protected] Received: 14 July 2015, Revised and Accepted: 24 August 2015 ABSTRACT Psoriasis is an autoimmune disease and further classed as a chronic inflammatory skin condition serving as a global burden. A moderate to severe psoriasis can be treated with conventional therapies. Less efficacy, poor patient compliance, and toxicity issues were the major problems associated with conventional therapies. The introduction of biologic therapy has a great impression on psoriatic treatment duration and enhanced quality of life in psoriasis patients. The new biologic therapies are tailor-made medications with the goal of more specific and effective treatment; less toxicity. The biologic therapy is aimed to target antigen presentation and co-stimulation, T-cell activation, and leukocyte adhesion; and pro-inflammatory cascade. They act as effective and safer substitute to traditional therapy. Secukinumab, certolizumab, itolizumab, golimumab, ustekinumab, adalimumab, infliximab etanercept, alefacept, etc. are the approved biologic with the global market. This review briefs about psoriasis pathogenesis, traditional treatments, and biologic therapies potential. Keywords: Psoriasis, Biologic, Non-biologic treatment. INTRODUCTION migration, potentiation of Th1 type of response, angiogenesis, and epidermal hyperplasia [7]. Psoriasis is an autoimmune disease and further classed as a chronic inflammatory skin condition with prevalence ranging 1-3% in the TNF- is plays vital role in the pathogenesis of psoriasis. It acts by world [1].
    [Show full text]
  • Downloaded Here
    Antibodies to Watch in a Pandemic Dr. Janice M. Reichert, Executive Director, The Antibody Society August 27, 2020 (updated slides) Agenda • US or EU approvals in 2020 • Granted as of late July 2020 • Anticipated by the end of 2020 • Overview of antibody-based COVID-19 interventions in development • Repurposed antibody-based therapeutics that treat symptoms • Newly developed anti-SARS-CoV-2 antibodies • Q&A 2 Number of first approvals for mAbs 10 12 14 16 18 20 Annual first approvals in either the US or EU or US the either in approvals first Annual 0 2 4 6 8 *Estimate based on the number actually approved and those in review as of July 15, with assumption of approval on the first c first the on of approval assumption 15, with as July of review in those and approved actually number the on based *Estimate Tables of approved mAbs and antibodies in review available at at mAbs ofand available in antibodies approved review Tables 1997 98 99 2000 01 02 03 Year of first US or EU approval or EU US of first Year 04 05 06 https://www.antibodysociety.org/resources/approved 07 08 09 10 11 12 13 14 15 Non-cancer Cancer 16 - antibodies/ 17 ycl 18 e. 19 2020* First approvals US or EU in 2020 • Teprotumumab (Tepezza): anti-IGF-1R mAb for thyroid eye disease • FDA approved on January 21 • Eptinezumab (Vyepti): anti-CGRP IgG1 for migraine prevention • FDA approved on February 21 • Isatuximab (Sarclisa): anti-CD38 IgG1 for multiple myeloma • FDA approved on March 2, also approved in the EU on June 2 • Sacituzumab govitecan (Trodelvy): anti-TROP-2 ADC for triple-neg.
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
    [Show full text]
  • Psoriasis Review
    JULY 2018 VOL 14 NUMBER 2 PSORIASIS REVIEW Included in this Issue 1 Top 5 Research and Clinical Papers IPC’S SEMI-ANNUAL REVIEW OF THE • Clinically resolved psoriatic lesions TOP 5 PAPERS: JULY–DECEMBER 2017 contain psoriasis-specific IL-17- producing αβ T cell clones • Psoriasis and suicidality: A systematic Every 6 months, IPC’s board and councilors recommend and vote on articles that review and meta-analysis make the greatest impact on psoriasis research. The 5 papers that received the • An analysis of IL-36 signature genes most votes for articles published July through December 2017 are reviewed here. and individuals with IL1RL2 knockout Summaries and commentaries were written by this issue’s co-editors, Dr. Colby mutations validates IL-36 as a Evans, Evans Dermatology, Austin, Texas, United States, and Dr. Nancy Podoswa, psoriasis therapeutic target Hospital General Regional No. 1 Dr. Carlos MacGregor Sanchez Navarro, Mexican • Coronary plaque characterization in psoriasis reveals high-risk features Institute of Social Security, Mexico City, Mexico. that improve after treatment in a prospective observational study 1. Residual T-cell clones in both active and resolved • Association between skin and aortic vascular inflammation in patients psoriatic plaques may reinitiate disease if treatment with psoriasis: a case-cohort study stops using Positron Emission Tomography/ Computed Tomography Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing 2 A Letter from the President αβ T cell clones. Matos TR, O’Malley JT, Lowry EL, et al. J Clin Invest. 2017 Nov 1;127(11):4031-4041. doi: 10.1172/JCI93396. Epub 2017 Sep 25.
    [Show full text]
  • An Anti-CD6 Monoclonal Antibody (Itolizumab)
    Saavedra et al. Immunity & Ageing (2020) 17:34 https://doi.org/10.1186/s12979-020-00207-8 RESEARCH Open Access An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients Danay Saavedra1* , Ana Laura Añé-Kourí2, Naivy Sánchez3, Lázaro Manuel Filgueira4, Julio Betancourt4, Carlos Herrera4, Leniel Manso4, Elibet Chávez5, Armando Caballero4, Carlos Hidalgo3, Geydi Lorenzo1, Meylan Cepeda1, Carmen Valenzuela1, Mayra Ramos1, Kalet León1, Zaima Mazorra1 and Tania Crombet1 Abstract Background: Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around the world has been placed. In Cuba, the first case of COVID-19 was reported on March 11. Elderly with multiple comorbidities have been the most risky population. Although most patients present a mild to moderate disease, some have developed severe symptoms. One of the possible mechanisms underlying rapid disease progression is a cytokine storm, in which interleukin (IL) -6 seems to be a major mediator. Itolizumab is a humanized recombinant anti-CD6 monoclonal antibody (MAb), with the ability of reducing serum interferon gamma (INF-γ), tumour necrosis factor alpha (TNFα) and IL-6. Based on these previous results in patients with psoriasis and rheumatoid arthritis, an expanded access clinical trial was approved by the Cuban regulatory agency for COVID-19 critically, severely and moderately ill patients. Results: We show here a short kinetic of IL-6 serum concentration in the first 24 COVID-19 patients treated with itolizumab. Most of patients were elderly with multiple comorbidities. We found that with one itolizumab dose, the circulating IL-6 decreased in critically and severely ill patients, whereas in moderately ill patients the values didn’t rise as compared to their low baseline levels.
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • Medical Product Quality Report – COVID-19 Issues
    Medical Product Quality Report – COVID-19 Issues Issue 9. February 2021 The document has been produced by the Medicine Quality Research Group, Centre of Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford This report was prepared by Kerlijn Van Assche, Céline Caillet and Paul Newton of the Medicine Quality Research Group, that is part of the Infectious Diseases Data Observatory (IDDO) and MORU Tropical Health Network, Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford, UK. The Globe system was developed by Clark Freifeld (HealthMap, Boston Children’s Hospital, North Eastern University) and Andrew Payne (IDDO), Alberto Olliaro (IDDO) and Gareth Blower (ex-IDDO) with curation of the English reports by Konnie Bellingham, Kitignavong Inthaphavanh and Vayouly Vidhamaly, linked to the Lao- Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR. This document is open access but we would be grateful if you could cite it as: Medicine Quality Research Group, University of Oxford. Medical Product Quality Report – COVID-19 Issues. Issue 9, February 2021. The work is kindly supported by the Bill&Melinda Gates Foundation, the University of Oxford and the Wellcome Trust. March 31th, 2021 2 Contents 1. Summary of findings ........................................................................................... 4 2. Introduction ........................................................................................................
    [Show full text]
  • Medical Product Quality Report – COVID-19 Issues
    Medical Product Quality Report – COVID-19 Issues Issue 8. January 2021 The document has been produced by the Medicine Quality Research Group, Centre of Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford This report was prepared by Kerlijn Van Assche, Céline Caillet and Paul Newton of the Medicine Quality Research Group, that is part of the MORU Tropical Health Network and Infectious Diseases Data Observatory (IDDO), Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford, UK. The Globe system was developed by Clark Freifeld (HealthMap, Boston Children’s Hospital, North Eastern University) and Andrew Payne (IDDO), Alberto Olliaro (IDDO) and Gareth Blower (ex-IDDO) with curation of the English reports by Konnie Bellingham, Kitignavong Inthaphavanh and Vayouly Vidhamaly, linked to the Lao- Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR. This document is open access but we would be grateful if you could cite it as: Medicine Quality Research Group, University of Oxford. Medical Product Quality Report – COVID-19 Issues. Issue 8, January 2021. The work is kindly supported by the Bill&Melinda Gates Foundation, the University of Oxford and the Wellcome Trust. March 3th, 2021 2 Contents 1. Summary of findings ........................................................................................... 4 2. Introduction ........................................................................................................
    [Show full text]
  • Soluble Ligands As Drug Targets
    REVIEWS Soluble ligands as drug targets Misty M. Attwood 1, Jörgen Jonsson1, Mathias Rask- Andersen 2 and Helgi B. Schiöth 1,3 ✉ Abstract | Historically, the main classes of drug targets have been receptors, enzymes, ion channels and transporters. However, owing largely to the rise of antibody- based therapies in the past two decades, soluble protein ligands such as inflammatory cytokines have become an increasingly important class of drug targets. In this Review, we analyse drugs targeting ligands that have reached clinical development at some point since 1992. We identify 291 drugs that target 99 unique ligands, and we discuss trends in the characteristics of the ligands, drugs and indications for which they have been tested. In the last 5 years, the number of ligand-targeting drugs approved by the FDA has doubled to 34, while the number of clinically validated ligand targets has doubled to 22. Cytokines and growth factors are the predominant types of targeted ligands (70%), and inflammation and autoimmune disorders, cancer and ophthalmological diseases are the top therapeutic areas for both approved agents and agents in clinical studies, reflecting the central role of cytokine and/or growth factor pathways in such diseases. Drug targets In the twentieth century, drug discovery largely involved far more challenging to achieve with small- molecule Pharmacological targets, such the identification of small molecules that exert their drugs. Protein ligands have been successfully targeted as proteins, that mediate the therapeutic effects by interacting with the binding sites by many drugs since the first FDA approval of the desired therapeutic effect of of endogenous small- molecule ligands such as neuro- ligand- targeting agents etanercept and infliximab in a drug.
    [Show full text]